Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 5/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430433 | 0.90 | MAPK1 (0.40) | MAPK1SMN1; SMN2KMT2AHTR1FACKR3 | |
| SCHEMBL14430494 | 0.88 | L3MBTL1 (0.40) | SIGMAR1ALDH1A1L3MBTL1 | |
| SCHEMBL14430491 | 0.84 | HTR2C (0.38) | SRD5A1SIGMAR1BACE1 | |
| SCHEMBL5199209 | 0.84 | MAPK1 (0.42) | MAPK1SMN1; SMN2KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL14430444 | 0.84 | MAPK1 (0.39) | MAPK1SMN1; SMN2KMT2AHTR1FL3MBTL1 | |
| SCHEMBL14430564 | 0.84 | KDM1A (0.44) | MAPK1SMN1; SMN2KMT2AHTR1FSRD5A1 | |
| SCHEMBL14430441 | 0.83 | SMN1; SMN2 (0.41) | MAPK1SMN1; SMN2KMT2ABACE1 | |
| SCHEMBL5199451 | 0.83 | MAPK1 (0.41) | MAPK1SMN1; SMN2KMT2ASRD5A1 | |
| SCHEMBL14430442 | 0.82 | SLC6A4 (0.42) | MAPK1SMN1; SMN2SIGMAR1ALDH1A1BACE1 | |
| SCHEMBL14430365 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | claimed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | claimed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | MAPK1 664/4885SMN1; SMN2 46/4885KMT2A 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.